AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer's disease (AD)
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein